Authors: De Gruttola, VG Clax, P DeMets, DL Downing, GJ Ellenberg, SS Friedman, L Gail, MH Prentice, R Wittes, J Zeger, SL

Citation: Vg. De Gruttola et al., Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health Workshop, CONTR CL TR, 22(5), 2001, pp. 485-502

Authors: Maiman, M Watts, DH Andersen, J Clax, P Merino, M Kendall, MA

Citation: M. Maiman et al., Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: A randomized trial, OBSTET GYN, 94(6), 1999, pp. 954-961

Authors: Wang, Y Livingston, E Patil, S McKinney, RE Bardeguez, AD Gandia, J O'Sullivan, MJ Clax, P Huang, S Unadkat, JD

Citation: Y. Wang et al., Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonate: An AIDS clinical trials group study, J INFEC DIS, 180(5), 1999, pp. 1536-1541